Search Results - "Kok, T.C"

Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer by van der Burg, M.E.L, Onstenk, W, Boere, I.A, Look, M, Ottevanger, P.B, de Gooyer, D, Kerkhofs, L.G.M, Valster, F.A.A, Ruit, J.B, van Reisen, A.G.P.M, Goey, S.H, van der Torren, A.M.E, ten Bokkel Huinink, D, Kok, T.C, Verweij, J, van Doorn, H.C

“…Abstract Background Weekly paclitaxel/carboplatin might improve survival in platinum-resistant epithelial ovarian cancer (EOC). We compared efficacy of…”
Get full text

3049 POSTER Epoetin Alfa and Darbepoetin Alfa in Clinical Practice in Patients With Chemotherapy Induced Anemia in the Netherlands (EVALUATE) by van Groeningen, C.J, Kok, T.C, Biesma, B, Melissant, C.F, de Klerk, G, Brok, R.G.P.M, Lahaye, M, Milek, R.L.B

Get full text

Changes in cell wall polysaccharides of green bean pods during development by Stolle-Smits, T, Beekhuizen, J.G, Kok, M.T.C, Pijnenburg, M, Recourt, K, Derksen, J, Voragen, A.G.J

“…The changes in cell wall polysaccharides and selected cell wall-modifying enzymes were studied during the development of green bean (Phaseolus vulgaris L.)…”
Get full text

8171 POSTER Prevention of nail disorders by cooling of nails and fingertips in patients treated with docetaxel-based chemotherapy by Weterman, M.J, Bijl, J, Westermann, A.M, Kok, T.C, Nortier, J.W.R

Get full text

An insight into clinicians’ practices in breaking bad news of oral cancer diagnosis by Mohd Desa, S.N.F., Doss, J.G., Kadir, K., Ch’ng, L.L., Kok, T.C., Jelon, M.A., Yahya, M.R., Parumo, R., Chong, S.M.Y., Shim, C.K.

“…Communication is an integral component of effective healthcare delivery to patients, and this includes breaking bad news (BBN). However, clinicians in…”
Get full text

Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with α-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial by Wagener, D.J.T, Wils, J.A, Kok, T.C, Planting, A, Couvreur, M.L, Baron, B

“…A randomised phase II study of 5-fluorouracil (5-FU) plus cisplatin (CDDP) with or without α-interferon 2b was performed in patients with pancreatic cancer…”
Get full text

The Effects Of CO2 Laser On Oral Lichen Planus And Lichenoid Lesions by Kok, T.C., Ong, S. T.

Get full text

High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer by Wils, J, Blijham, G.H, Wagener, Th, De Greve, J, Jansen, R.L.H, Kok, T.C, Nortier, J.W.R, Bleiberg, H, Couvreur, M.L, Genicot, B, Baron, B

Get full text

Chemotherapy in oesophageal cancer by Kok, T.C.

Get full text

No evidence of known types of human papillomavirus in squamous cell cancer of the oesophagus in a low-risk area by Kok, T.C., Nooter, K., Tjong-A-Hung, S.P., Smits, H.L., Schegget, J.Ter

“…Controversial results regarding the presence and role of human papillomavirus in the development of oesophageal squamous cell carcinoma have been published. We…”
Get full text

High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group by Wils, J, Blijham, G.H, Wagener, Th, De Greve, J, Jansen, R.L.H, Kok, T.C, Nortier, J.W.R, Bleiberg, H, Couvreur, M.L, Genicot, B, Baron, B

“…The aim of this study was to investigate whether N-(phosphonacetyl)- l-aspartic acid (PALA) can enhance the activity of low-dose methotrexate (LD-MTX)…”
Get full text

13- Cis-retinoic acid and alphainterferon in advanced squamous cell cancer of the oesophagus by Kok, T.C., van der Gaast, A., Splinter, T.A.W.

Get full text

An adaptive block encoding technique for hybrid ARQ schemes by Kok, T.C.

“…Satellite communications using packetised systems is becoming popular. Transmitting information packets via these satellite channels with varying noise…”
Get full text

5-Fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area by Kok, T. C., van der Gaast, A., Splinter, T. A. W.

“…Background: The results of chemotherapy against gastric cancer or esophageal squamous cell carcinomas cannot be generalized to adenocarcinomas of the…”
Get full text

Disease monitoring by the tumour markers Cyfra 21.1 and TPA in patients with non-small cell lung cancer by van der Gaast, A., Kok, T.C., Kho, G.S., Blijenberg, B.G., Splinter, T.A.W.

“…We evaluated the use of two tumour markers Cyfra 21.1 and tissue polypeptide antigen (TPA) for disease monitoring. Assessment of response to WHO criteria was…”
Get full text

Prognostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small cell lung cancer by van der Gaast, A, Schoenmakers, C H, Kok, T C, Blijenberg, B G, Hop, W C, Splinter, T A

“…In this study, we evaluated the prognostic value of the tumour marker, tissue polypeptide-specific antigen (TPS), in 203 patients with non-small cell lung…”
Get more information

Phase II study of carboplatin and etoposide as a first line regimen in patients with metastatic breast cancer by van der Gaast, A, Bontenbal, M, Planting, A S, Kok, T C, Splinter, T A

“…The data available on the role of carboplatin and etoposide in breast cancer, especially in patients with no or minimal prior therapy are limited. We performed…”
Get more information

Growing teratoma syndrome successfully treated with lymphoblastoid interferon by van der Gaast, A, Kok, T C, Splinter, T A

“…In most instances mature teratoma can be successfully resected following chemotherapy for advanced testicular cancer. However, some patients may eventually die…”
Get more information

Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer by de Wit, R, Tesselaar, M, Kok, T C, Seynaeve, C, Rodenburg, C J, Verweij, J, Helle, P A, Stoter, G

“…47 patients with advanced urothelial cancer and no prior chemotherapy were randomly assigned to therapy with either carboplatin or iproplatin. Both platinum…”
Get more information

Correlation between changes in the tumour markers CA-M26 and CA-M29 and standard response evaluation in patients with metastatic breast cancer by van der Gaast, A, Hulshof, C, Kok, T C, van Loon, E, Splinter, T A

“…In this study we correlated response evaluated by standard WHO criteria to strict defined criteria of tumour marker response in 63 patients with metastatic…”
Get more information